Sickle cell anemia, expert, “Crizanlizumab valid alternative to standard therapy”

“Crizanlizumab is a very innovative drug because it could help us doctors manage even those patients who have failed or do not accept standard therapies such as hydroxyurea / hydroxycarbamide (HU / HC).” Thus Lucia De Franceschi, associate professor of Internal Medicine at the University of Verona, explained the potential of Adakveo® (Crizanlizumab), a drug for the prevention of vaso-occlusive crises. Novartis announced that the Italian Medicines Agency (AIFA) has approved reimbursement.